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 Tumors represent a challenge for the modern therapies, and divers 
studies have shown that different factors are involved in both 
tumorigenesis and processes of tumor development. Therefore, 
further investigations and descriptions of inter-influences and 
interactions between the nervous system, the tumoral process and 
pharmacotherapies might lead to novel advances and applications, 
not only in the therapeutical approaches but also in the experimental 
design. 
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1. INTRODUCTION 
Tumors constitute a major health problem, and due to the complex mechanisms tumoral processes 
involve, this area remains full of challenges for both modern medical practice and pharmacological 
researches. However, biochemical and genetic descriptions of tumorigenesis and tumor development, similar 
to what has been suggested for normal organ homeostasis, should be regarded as a result of constant and 
mutual interactions between tumor cells and their surrounding microenvironment. In fact, in addition to the 
complex physiological and biochemical factors tumoral processes involve, numerous observations concluded 
that tumor cells, as biological entities, interact with their surrounding cells, lymphatic circulation, blood 
circulation and nervous system. For instance, lymphoangiogenic factors influence the metastatic process [1], 
whereas tumor cells have the ability to foster neoangiogenesis [2]. Thus, the concept of limiting the tumors 
development via drugs that stop blood supply [3, 4] came out.  
Since novel neurological aspects of tumors were more elucidated, many evidences have further 
shown that tumors growth process is also related to the nervous system. Indeed, The existence of nerve 
endings within bladder [5], eye [6],  prostate [7], breast [8, 9], pancreatic tumors [10] and also within other 
types of cancers like colon cancer [11, 12] illustrates well such concept. More important, numerous 
neurotransmitters influence tumor vascularization [13, 14] and cells migration[15, 16], in addition, they may 
also suppress the immune response in cancer [17]. These influences are increased by the ability of the cancer 
cells to secret neurogenic factors [18-20] which influences neurons development.  
Among the known neurotransmitters, which are likely over 100 [21], some constitute important 
factors of tumoral processes such as cells migration, stimulation and proliferation. Moreover, 
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immunomodulation theories suppose that a potential targeting of those neurotransmitters’ receptors by 
pharmakons might lead to new therapies especially if pharmacologic elements, such as the factors that 
influence the function of those receptors, including receptor surrounding chemical environment and the kind 
of cell junctions [22], are defined within a tumor context and then, taken into consideration during the related 
pathogenesis description and the drugs development approaches. 
 
 
2. NEUROPHARMACOLOGY AND ANTITUMOR THERAPIES 
A number of illustrative findings and advances exemplify the increasing potentials that 
neuropharmacology has among the existent antitumor therapies. For instance, the study of  serotonin, which 
is excessively synthesized by breast cancer cells to sustain their growth  [23], and the corresponding 
signaling system, has led to new therapeutics such as the three serotonin receptor inhibitors paliperidone, 
pimozide and risperidone that might have an adjunctive role in glioblastoma treatment via growth factors 
deprivation[24]. As a second example, whereas the activation of the β-adrenergic receptors (βAR) could 
modulate both development and progression of ovarian cancer [13, 25] and  mammary tumors cells [26, 27], 
it increases the metastasis process in breast, lung and colon cancer models [28-30]. Moreover, epinephrine 
and norepinephrine, which are βAR agonists, induce the secretion of vascular endothelial growth factor 
(VEGF) and interleukin-6(IL-6) by cancer cells [13, 31, 32] thus, illustrate the impact of the two βAR 
agonists on cell growth and proliferation. Importantly, a preventive effect of propranolol (a β-blocker) on the 
development of pancreatic ductal adenocarcinoma in mice [33] has been reported which, therefore, presents 
β-blockers as potential candidates for the treatment of some catecholaminergic system-related tumors. Other 
studies, on the effects of both nicotine and 4-(methylnitrosoamino)-1-(3-pyridyl)-1 butanone (NNK, a 
tobacco-specific nitrosamine) on human small cell lung cancer (SCLC), suggested a link between tumors 
processes and autonomic nervous system [34]. Consequently, laboratories are investigating the potential use 
of acetylcholine receptor antagonists as an anticancer therapy. The results showed that some muscarinic 
antagonists have the ability to stop tumor progression in nude mice [35], whereas NSCLC nicotinic 
acetylcholine receptor (n-AChRs) antagonists have a pro-apoptotic effect on NSCLC  [36]. Furthermore, 
muscarinic acetylcholine receptor M3 (M3R) antagonists might constitute an adjuvant for SCLC treatment 
[37] and, together with previous observations, strengthens the promising area of oncological 
neuropharmacology. 
Additionally, many temporal cells express glutamate and glutamate receptor subunits. Such cells 
constitute tissues of colorectal cancer [38, 39], glioma cancer [40-42], gastric cancer [43], prostate cancer 
[44], oral squamous cell carcinoma [45], melanoma [46, 47] and osteosarcoma [48]. Importantly, glutamate 
has been shown to play a role in cancer [48, 49], thus we may target glutamate receptors to obtain an 
anticancer pharmacotherapy. Whereas cancers such as colon, gastric, ovarian and breast cancers have an 
increased gamma aminobutyric acid (GABA) content [50-53], numerous papers have pointed a correlation 
between the GABAergic system and both oncogenesis [54, 55] and tumor cells migration [56], indicating a 
local antitumor effect of  GABA [57, 58]. Therefore, GABA and its analogues, such as baclofen, constitute 
candidates to anticancer therapy and drug development [59]. Another neurotransmitter, which is the 
dopamine, plays also an important role within the neuro-tumoral interactions and has effects on both cancer 
growth and anticancer drugs. Indeed, it blocks VEGF–induced angiogenesis of endothelial progenitors in the 
bone marrow [60, 61], in addition, dopamine contributes in the growth diminution of other cancers such as 
stomach, breast and colon cancers [60, 62]. Furthermore; dopamine, if given with conventional anticancer 
drugs, like doxorubicin or 5-fluorouracil (5-FU), produces synergistic effects [60] which shows the important 
role of dopaminergic pathway within cancer pathogenesis. 
Another neuro-oncological interactions example is represented by tachykinins pathways. 
Tachykinins are synthesized by neuronal, endothelial, and epithelial cells, in addition of macrophages [63].  
In human species, tachykinins system includes substance P (SP), neurokinin A, neurokinin B and their 
receptors that are NK1, NK2 and NK3 respectively  [63]. Among tachykinins system constituents, SP and its 
receptor NK1 are overexpressed in several cancers including breast, ovarian, prostate, pancreas, thyroid 
cancers and glioblastoma [63]. While SP and its receptors confer oncogenic properties to breast cancer cells 
[64-67], the proliferation of the cancer cells has been shown to be the result of NK1 receptors’ activation by 
SP. Therefore, the pharmacologic applications that inhibitors, of either NK1 binding to SP [68] or SP activity 
[69], are under investigation to provide new therapeutic arsenal [70].  
   Not only neurotransmitters, but also different active compounds (mainly drugs), interfere, either directly or 
indirectly, with the tumor process. Such compounds might interact with the neuronal networks as agonists, 
antagonists or other kind of neuro-activity modulators, thus influence the tumors prognoses in many ways 
depending on specific factors including the drugs’ pathways and dosages, in addition of the nature of the 
neurotransmitters  implicated within the drugs’ mechanisms. 
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3. TUMORS AND PSYCHIATRY   
As described above, there are both complex and deep reactions and interactions between several 
neurotransmitters and cancer processes. Moreover, among those neurotransmitters, some might either 
influence or be influenced by some therapies. Because neurotransmitters’ concentration and secretion are 
strongly linked to the pschycological and the psychiatric profiles of the patient; the mood, for example, 
constitutes an important factor that can strongly influence tumoral processes [13, 71, 72]. Such influence is 
due to the changements of the neurotransmitters’ activity that accompany the psychological or the psychiatric 
variations. These variations may also modify the anticancer drugs’ effects and eventually, have an impact of 
the therapy efficacy. For example, the concentration of epinephrine and norepinephrine increases as a 
consequence of  psychological and social pressures [73], which is likely to enhance the probability of  the 
cancer initiation [25, 74]. Such approach needs further investigation, especially in the light of the different 
investigations that describe the psychiatric disorders as  neural system dysfunctions [75], thus suggest that a 
factor (or a drug) that interfere with an element of this neural system (receptor, enzymatic pathway…etc) 
might influence the other elements of the same neural system’s network that include the neurotransmitters 
and therefore, interfere with the tumoral process.  
Following this line of thought, and due to the impact they have on tumoral process, pschycological 
and psychiatric profiles should be taken into consideration mainly during both drugs-testing investigations 
and therapeutical approaches [70] for oncology studies, especially that the same anti-tumor treatment may 
not have the same efficacy inside a population because the psychological or the psychiatric variations that 
exist between the individuals of this population. 
 
 
4. PERSPECTIVES 
Descriptions of both clinical and physiological aspects of the possible interactions between 
neurotransmitters, tumors evolution and therapeutic mechanisms, together with the new elements about the 
different onco-biological systems and their related molecular and enzymatic pathways, will surely contribute 
in further elucidating the related pathogenic and pharmacodynamical phenomena, therefore, lead to novel 
explanatory theories. Such approach might constitute the starting point of new therapies via screenings of 
potential chemical, natural or immunological agonists and antagonists of the different tumor-related 
neuroreceptors. Some chemicals, used in laboratories as regents or solvents, and for which biological and 
pharmacological properties have been reported [76] , could represent candidate to antitumor drug 
development as well and, thus might require more investigations. 
On the other hand, the strong interactions between the pharmacological factors, the oncological 
profile and the neurological status, in addition to the complexity of the neuronal networks implicated within 
the different oncogenesis pathways, make that the understanding of the related pharmacovigilance 
requires a high level of expertise. Both a detailed description of such pharmakons’ mechanisms of actions 
and whether they target and modify the tumor-related neuronal network system, remain highly important in 
any future drug design, on the one hand, and control the side effects due to the neural system complexity and 
interactions, on the other hand. 
Following this line of thought, strong and continuous collaborations between different experts, 
including psychologists, pharmacologists, neuroscientists and oncologists, will lead to the emergence of a 
new field within the modern medical sciences that would combine the divers factors implicated in the 
tumoral process. Such field could provide data and assistance not only for clinicians, to design appropriate 
treatments schema, but also for researchers to optimize their experimental conditions.  
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